These experimental data suggest that hepatic expression of RANKL may potentially be upregulated in NAFLD, while relevant data on hepatic OPG are still contradictory; however, the exact source, role, and regulation of these molecules in the liver are largely unknown. This evidence concerns the gene TNFRSF11B and metabolic dysfunction-associated steatotic liver disease.